Monitoring and treatment for cardiovascular risk

Background In many countries there is a gap between the clinical evidence for cardiovascular disease (CVD) prevention and implementation in clinical practice. Inadequate control of cardiovascular risk factors and underutilization of aspirin, statins, angiotensin converting enzyme inhibitors and [bet...

Full description

Saved in:
Bibliographic Details
Published in:Primary health care research & development 2010-01, Vol.11 (1), p.29-40
Main Authors: Rabinowitz, Israel, Hochman, Ohad, Luzzati, Rachel, Haifitz, Yelena, Shclar, Yuri, Kaykov, Natalia, Khemlin, Alexander, Kaffman, Michael, Tamir, Ada
Format: Article
Language:English
Subjects:
Ambulatory care
Cardiovascular disease
Cholesterol
Clinical medicine
Diabetes
Disease prevention
Heart attacks
Hypertension
Medical records
Metabolic disorders
Patients
Physicians
Primary care
Public health
Risk factors
Statins
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background In many countries there is a gap between the clinical evidence for cardiovascular disease (CVD) prevention and implementation in clinical practice. Inadequate control of cardiovascular risk factors and underutilization of aspirin, statins, angiotensin converting enzyme inhibitors and [beta]-blockers are well-established examples. The optimal approach to implementation of CVD prevention in clinical practice is still under debate. The screening and monitoring (SaM) approach is based on cyclic monitoring and individual treatment of patients with cardiovascular risk factors in the primary care setting. After achieving improvements in risk factor levels and in the use of preventive medications in a pilot study, it was decided to test the efficacy of this approach in a larger population at risk. Methods Five primary care clinics adopted the SaM approach. A total of 1622 patients with established CVD, diabetes mellitus or hypertension were assessed by their family physicians for cardiovascular risk factors and use of medications for cardiovascular risk reduction. Interventions were made according to accepted clinical guidelines. Cardiovascular risk factor levels and the use of medications for CVD prevention were retrospectively analyzed. Results The results demonstrated significant reductions in blood pressure, hemoglobin A1c and low-density lipoprotein-cholesterol levels, as well as significant increases in the use of medications for CVD prevention. Conclusion A systematic approach to CVD reduction, with an emphasis on multiple risk factor assessment and use of preventive medications in patients at cardiovascular risk, yielded significant improvements in measures of the quality of preventive care.
ISSN:1463-4236
1477-1128
DOI:10.1017/S1463423609990338